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httpRole of Girdin in intimal hyperplasia in vein grafts
and efﬁcacy of atelocollagen-mediated application
of small interfering RNA for vein graft failure
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Kimihiro Komori, MD, PhD,b and Masahide Takahashi, MD, PhD,a,c Nagoya and Sagamihara, Japan
Objective: Intimal hyperplasia is a major obstacle to patency in grafted veins. Although migration and proliferation of
vascular smooth muscle cells (SMCs) pivotally affect the vascular remodeling process, no therapy has been established to
prevent intimal hyperplasia of vein grafts. We previously reported that the actin-binding protein Girdin crucially affects
arterial remodeling. In this study, we investigated the role of Girdin in venous SMCs and evaluated a therapeutic strategy
for vein graft failure in vivo using small interfering RNA (siRNA) that targets Girdin.
Methods: We investigated the relationship between Girdin expression and intimal hyperplasia using a rabbit vein graft
model. Vein grafts under low-ﬂow conditions were performed in Japanese White rabbits. For in vitro analyses, we isolated
primary venous SMCs from vein graft neointima. siRNA that targets Girdin was mixed with atelocollagen, which
stabilizes and releases nucleic acid reagents slowly and is applied perivascularly to the vein grafts at operation. Intimal
hyperplasia was evaluated 4 weeks later.
Results: In the rabbit model, increased Girdin expression was seen in the neointima after the grafting operation. Using
primary venous SMCs, we showed that Girdin is required for rearrangement of the actin cytoskeleton in venous SMCs
and that siRNA-mediated Girdin knockdown signiﬁcantly reduced venous SMC migration and proliferation. Girdin
knockdown via perivascular application of siRNA using atelocollagen markedly reduced intimal thickening after the
grafting operation.
Conclusions: Depletion of Girdin attenuated venous SMCs migration and proliferation in vitro and intimal hyperplasia in
vein grafts in vivo. Our ﬁndings suggest that Girdin affects migration and proliferation of vascular SMCs in vein grafts
and that controlled release of Girdin siRNA using atelocollagen could be a novel therapeutic strategy for vein graft
failure. (J Vasc Surg 2014;60:479-89.)
Clinical Relevance: Intimal hyperplasia is a major obstacle to patency after vein grafting. Although migration and
proliferation of vascular smooth muscle cells pivotally affect the vascular remodeling process, no therapy has been
established to prevent intimal hyperplasia of vein grafts. Here, we report that depletion of the actin-binding protein
Girdin attenuated migration and proliferation of venous smooth muscle cells in vitro and intimal hyperplasia in vein
grafts in vivo. Our ﬁndings indicate that perivascular application of Girdin small interfering RNA using atelocollagen
could be a novel therapeutic strategy for vein graft failure.Cardiovascular disease is a major cause of death and artery bypass grafting in treating ischemia resulting from
disability in developed countries. More than 2200 Ameri-
cans die of cardiovascular disease each day, an average of
one death every 39 seconds.1 An autologous vein is the
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://dx.doi.org/10.1016/j.jvs.2013.06.080occlusive vascular disease. However, the long-term success
of this operation is limited by vein graft occlusion caused
by intimal hyperplasia and superimposed atherosclerosis,
with worse patency for poor runoff vessels in which hemody-
namic factors, such as low-ﬂow velocity and low shear stress,
cause intimal thickening.2,3
Increased proliferation of terminally differentiated
vascular smooth muscle cells (SMCs) contributes signiﬁ-
cantly to lesional neointima formation.4 Neointimal SMCs
are controversially reported to originate from local vessel
walls, circulating progenitor cells, or from bone marrow.5-9
Despite many clinical trials, few models reﬂect the contribu-
tion of various cell types to neointimal development, nor has
a satisfactory therapeutic strategy been established.
The phosphatidylinositol 3-kinase (PI3K)/Akt system
regulates multiple cellular processes through phosphoryla-
tion of downstream substrates. The PI3K/Akt pathway
and its downstream components are also pivotal in vascular
remodeling.10 Girdin (girders of actin ﬁlaments), also
known as Ga-interacting vesicle-associated protein, is479
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at high levels in cell types that require remodeling of actin
ﬁlaments, cell migration, and proliferation such as SMCs,
neuroblasts, and cancer cells.11,15-19
We reported that Girdin affects migration and prolifer-
ation of arterial SMCs and regulates neointima formation
after arterial injury via Akt-mediated phosphorylation.18
However, little information is available about its functions
in venous SMCs, especially in vein grafts. Here, we studied
the roles of Girdin in migration and proliferation of venous
SMCs in vitro and found a combination of small interfering
RNA (siRNA) that targets Girdin and atelocollagen, which
allows its controlled release, to suppress signiﬁcantly
intimal hyperplasia in vein grafts in vivo. These ﬁndings
provide a novel strategy to prevent intimal hyperplasia.
METHODS
The animal experiments in this study were performed
in compliance with the guidelines of Nagoya University
Graduate School of Medicine and approved by the Animal
Care and Use Committee (Permit Number: 24084).
Antibodies. Rabbit anti-Girdin polyclonal antibody
was developed in-house against the 19 carboxyl-terminal
amino acids of Girdin and afﬁnity-puriﬁed with the immu-
nizing peptide.11 Other primary antibodies used in this
study were commercial sheep polyclonal anti-Girdin (R&D
Biosystems,Minneapolis,Minn),mousemonoclonal anti-a-
smooth-muscle actin (a-SMA) and anti-Ki-67 antibodies
(Dako, Glostrup, Denmark), mouse monoclonal anti-b-
actin antibody (Sigma, St. Louis, Mo), and rat monoclonal
anti-CD31 antibody (Dianova, Hamburg, Germany).
Vein graft model. Japanese White rabbits (2.5-3.0 kg)
were anesthetized by an intramuscular administration of ket-
amine (35mg/kg) and xylazine (10 mg/kg). The no-touch
technique was used to dissect a segment of right exter-
nal jugular vein (20-mm length; 3-mm width) through
a midline vertical neck incision. All branches were carefully
ligated with 8-0 polypropylene sutures and divided. Animals
were systemically heparinized (200 U/kg). The ipsilateral
common carotid artery was clamped distally and proximally,
and a graft was anastomosed in end-to-end fashion into the
divided artery with interrupted 8-0 polypropylene sutures.
Before wound closure, grafts were subjected to low-
ﬂow conditions, as described previously (poor runoff
model).20,21 The poor runoff model mimics clinical condi-
tions of vein grafts performed for ischemic extremities with
poor runoff. For poor runoff models, three of four distal
vessel branches were ligated after the external jugular
vein-to-carotid artery interposition (Fig 1, A).2,3 The distal
vessels remained patent in the normal runoff model.
Primary culture of venous SMCs. The experiments
were performed with primary cultures of venous SMCs
from rabbit vein grafts 4 weeks after bypass grafting. The
entire length of the vein grafts was immediately excised
under sterile conditions. The vein grafts were rinsed with
Hanks solution and opened lengthways. The neointima
was dissected from the underlying media. The separated
sheets of neointima were cut into small pieces ofw1 mm2,washed in Hanks solution, and incubated in Hanks solution
containing collagenase I (1 g/L; Funakoshi, Tokyo, Japan)
and elastase III (0.5 g/L; Sigma) for 90 minutes at 37C.
Thereafter, the cells were dispersed. The cell suspension
was centrifuged at 120 g for 4 minutes, resuspended, and
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM)
with 10% fetal bovine serum, 1% streptomycin/penicillin,
and 2 mM L-glutamine. The identity of SMCs was
conﬁrmed by immunostaining with anti-a-SMA antibody.
Venous SMCs at passages one to three were used in the
experiments.
RNA interference. siRNA-mediated knockdown of
Girdin was performed using “siRNA (B)” in vitro, as
described previously.11,18 In addition, we made two more
siRNAs for rabbit Girdin, as follows (sense sequence only):
si-rb1: 50-GGACCAACCUGGAUGAAUATT-30 (nucle-
otides 98-116), and
si-rb2: 50-GGCAGAACAUCCACUAGCATT-30 (nucle-
otides 4768-4786).
The 21-nucleotide synthetic duplexes with two 30-end
overhang dT were prepared by Qiagen (Valencia, Calif).
Venous SMCs were transfected with one of the siRNAs
(50 nM) or a 21-nucleotide irrelevant RNA (Qiagen) as
a control, using Lipofectamine RNAiMAX (Invitrogen,
Carlsbad, Calif), according to the manufacturer’s protocol.
siRNAs were successfully introduced into almost 100% of
SMCs using Lipofectamine RNAiMAX.
For the in vivo study, we used stabilized siRNAs, Dhar-
macon siSTABLE (Thermo Scientiﬁc, Lafayette, Colo). We
used atelocollagen-based in vivo siRNA/microRNA trans-
fection reagent AteloGene Local Use (Koken Co Ltd,
Tokyo, Japan). AteloGene is a highly puriﬁed type I collagen
derived from calf dermis by pepsin treatment. Before the
operation, siRNA-AteloGene complexes were prepared as
follows: 150 mL of AteloGene and 150 mL of a stabilized
siRNA solution (20 mM) were mixed, maintained at 4C,
and then used to coat the external surface of the vein graft.
This complex formed a gel after appropriate heat treatment
with a hair dryer for <10 seconds, which did not dry or
injure the vein grafts.20 This siRNA-containing gel remained
around the graft for at least 1 week.
Western blot analysis. Frozen rabbit vein grafts were
homogenized in radioimmunoprecipitation assay buffer
containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1%
nonyl phenoxypolyethoxylethanol, 0.1% sodium dodecyl
sulfate, and 0.1% sodium deoxycholate and rotated at
4 rpm for 2 hours at 4C. After protein concentrations
were measured, lysates were boiled at 100C for 2 minutes
in the presence of 2% b-mercaptoethanol. The lysates, con-
taining 30mg of proteins, were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Western blotting
was performed using standard protocols detailed in the
Supplementary Methods (online only).
Histopathology. Intact veins and vein grafts were ﬁxed
at 100 mm Hg infusion pressure for 20 minutes with 10%
neutral-buffered formalin and immersed for 40 hours in
10% neutral-buffered formalin. Three evenly spaced
segments (4-5mm apart) of the middle portion of each graft
Fig 1. Girdin localizes to vascular smooth muscle cells (SMCs) in the tunica media and neointima of vein grafts.A, Poor
runoff vein graft (VG) model with distal branches ligation is depicted. The inferior-most branch of the external carotid
artery (ECA) is the only outﬂow for the low-ﬂow graft. CCA, Common carotid artery; ICA, internal carotid artery.
B, Rabbit vein grafts at the indicated days postoperation underwent immunohistochemistry analysis using anti-Girdin
antibody. Note that these veins and vein grafts were dilated with infusion pressure during ﬁxation, and vascular walls
look thinner than under normal conditions. The scale bar¼ 100 mm.C,Western blot analyses showGirdin expression in
rabbit whole-vein grafts. The bar graph shows protein levels of Girdin (relative to b-actin) determined by densitometry in
whole-vein grafts harvested at the indicated days postoperation. The Girdin level in the intact vein was deﬁned as 1. The
error bars indicate the standard error of themean (n¼ 3 for each group). *P< .05.D,Vein grafts at 14 days postoperation
underwent immunoﬂuorescence staining using sheep immunoglobulin G (IgG) as a negative control or anti-Girdin
antibody (red) and anti-a-smooth muscle actin (SMA) antibody (green). Cell nuclei were labeled with 40,6-diamidino-
2-phenylindole. Upper and middle panels, Representative photomicrographs are at low magniﬁcations (scale bars ¼
200 mm). Lower panel, The boxed area is magniﬁed (scale bars ¼ 50 mm).
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with hematoxylin and eosin or elastica van Gieson. Intimal
and medial cross-sectional areas were measured, and the
neointimal thickness was measured at eight randomly
selected points for each section using MetaMorph software
(Universal Imaging, Ypsilanti, Mich).Immunohistochemical analysis. Sections were heated
in Target Retrieval Solution (pH 9.0; Dako) for antigen
retrieval, blocked with Protein Block Serum-Free Ready-
to-Use (Dako), incubated with primary antibodies, washed
in phosphate-buffered saline, and incubated with the
secondary antibody. Reaction products were visualized
JOURNAL OF VASCULAR SURGERY
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used hematoxylin.
Immunoﬂuorescence staining. Immunoﬂuorescence
staining was performed as previously described11; proto-
cols are detailed in the Supplementary Methods (online
only).
Quantiﬁcation of lamellipodia. We investigated the
increased number of cells with extended lamellipodia;
that is, the difference in the number of cells with extended
lamellipodia between before and after platelet-derived
growth factor (PDGF) stimulation. Note that cells with
lamellipodia at more than one-third (>120) of the cell
periphery were counted as cells with extended lamellipodia.
Cell migration and mitogenic activity assays. Direc-
tional cell migration of venous SMCs was stimulated in
a monolayer using an in vitro scratch wound assay, as previ-
ously described.15 Mitogenic activity was measured using
the Cell Proliferation Reagent WST-1 assay (Roche
Applied Science, Penzberg, Germany). Protocols for these
assays are detailed in the Supplementary Methods (online
only).
Detection of cell proliferation and apoptosis in vivo.
Nuclei positive for Ki-67 or terminal deoxynucleotide
transferase-mediated deoxy uridine triphosphate nick-end
labeling (TUNEL) were evaluated, as previously describ-
ed.18,20 To detect proliferation, sections of rabbit vein grafts
were blocked and incubated with a mouse monoclonal anti-
Ki-67 antibody overnight at 4C. Thereafter, sections were
incubated with EnVisionþ System-HRP Labelled Polymer
Anti-mouse (Dako). To detect apoptosis, we used the
Apoptosis in situ Detection Kit (Wako, Osaka, Japan),
according to the manufacturer’s protocol. In each experi-
ment, hematoxylin was used for nuclear counterstaining.
Numbers of Ki-67þ and TUNELþ cells were calculated as
Ki-67 or TUNEL indices (Ki-67þ or TUNELþ cells/total
cells  100), respectively.
Statistical analysis. Values are expressed as means 6
standard error of the means. Signiﬁcance (P < .05) was
determined using the Student t-test or Bonferroni post
hoc analysis.
RESULTS
Increased expression of Girdin in neointima of vein
grafts. To examine the effects of Girdin in vein grafts, Gir-
din expression in cross-sections prepared from rabbit vein
grafts with poor runoff was assessed immunohistochemi-
cally. Girdin expression was detected in the media of the
intact vein that was a-SMAþ (Fig 1, B; Supplementary Fig 1,
online only). As the neointima thickened, enhanced Girdin
expression was observed in the neointima rather than in the
media (Fig 1, B). Girdin expression in the neointima peaked
14 days after bypass grafting and gradually decreased
thereafter.
Girdin expression in whole intact veins and vein grafts
with poor runoff was studied using Western blot analyses
(Fig 1, C). Only weak Girdin expression was detected in
intact veins. Expression levels increased after vein grafting
and peaked at day 14 after bypass grafting, which wasconsistent with immunohistochemical analysis. Girdin
localization was conﬁrmed in 14-day-old vein grafts by
immunoﬂuorescence staining using anti-Girdin antibody
and anti-a-SMA antibody (Fig 1, D). Girdin localizes to a-
SMAþ cells in the media and neointima. Cells that were
both Girdinþ and a-SMAþ existed mainly in the vein graft
neointima at 14 days after bypass grafting. This ﬁnding
suggests that Girdin is upregulated in the developing
neointima.
Girdin is upregulated in the vein grafts with poor
runoff. To determine whether Girdin affects intimal
hyperplasia in vein grafts, we compared Girdin expression
in vein grafts with poor and normal runoff. The neointima
was clearly thickened in vein grafts with poor runoff
compared with normal runoff models (Fig 2, A), consis-
tent with previously reported data.3 All vein grafts of both
models were patent when they were excised. Western blot
analyses showed that Girdin expression markedly increased
during neointima formation at 7 and 14 days after bypass
grafting in poor runoff models compared with normal
runoff models (Fig 2, B).
Rearrangement of actin cytoskeleton of venous
SMCs requires Girdin. We examined Girdin localization
using primary venous SMCs isolated from the neointima of
vein grafts. Immunocytochemical analysis using anti-
Girdin and anti-b-actin antibodies showed Girdin local-
ized on actin stress ﬁbers in venous SMCs (Fig 3, A), as
previously observed in other cell types.15,18 To investigate
Girdin function in venous SMCs, we observed the effect of
RNA-mediated interference on actin cytoskeletons in these
cells. We introduced three siRNAs targeting Girdin
(siRNA [B], si-rb1, si-rb2) and an irrelevant siRNA
(control siRNA) into venous SMCs. Although serum-
starved controls and Girdin-depleted venous SMCs
showed no apparent morphologic differences, formation of
thick stress ﬁbers signiﬁcantly decreased in Girdin-depleted
cells stimulated with serum compared with control cells
(Fig 3, B). Moreover, after stimulation with PDGF-BB,
the leading-edge extension of lamellipodia was signiﬁ-
cantly attenuated, and only small membrane protrusions
could be seen in the Girdin-depleted cells (Fig 3, C). The
increased number of Girdin-depleted cells with extended
(>120) lamellipodia after PDGF stimulation was signiﬁ-
cantly lower than that of control cells, at 14.49 6 3.19 and
1.95 6 1.57 per 100 cells, respectively (n ¼ 3; P < .05;
Fig 3, D). These ﬁndings suggest that Girdin pivotally
affects actin remodeling of lamellipodia in migrating
venous SMCs.
Girdin depletion inhibits venous SMCs migration
and proliferation in vitro. Vascular SMCs migration and
proliferation are reported to be key events in intimal hyper-
plasia of vein grafts.4 We investigated whether Girdin
depletion inhibits venous SMCs migration in vitro using
wound healing assays (Fig 4, A). siRNA-mediated Girdin
knockdown resulted in signiﬁcantly reduced migration
distance by venous SMCs and fewer cells migrating into the
wounded area, compared with those of venous SMCs
transfected with control siRNA (n ¼ 3; P < .01; Fig 4, B
Fig 2. Girdin is upregulated in vein grafts with poor runoff. A,
Representative elastica van Gieson-stained sections of vein grafts
harvested at indicated days postoperation. The lower arrowheads
indicate the internal elastic lamina. The scale bar ¼ 100 mm. B,
Western blot analyses showed Girdin expression in rabbit whole-
vein grafts with poor or normal runoff. The bar graph shows
Girdin protein levels (relative to b-actin) determined by densi-
tometry in whole-vein grafts harvested at the indicated days
postoperation. The Girdin level in intact veins was deﬁned as 1.
The error bars show the standard error of the mean (n ¼ 3 for each
group). *P < .05.
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(WST)-1 assays to examine the effect of Girdin on venous
SMC proliferation. On day 4, proliferation of Girdin-
depleted cells was signiﬁcantly suppressed compared with
control cells (n ¼ 5; P < .01; Fig 4, D). These ﬁndings
show that Girdin depletion inhibits migration and prolif-
eration of venous SMCs in vitro, suggesting that use of
siRNA targeting Girdin could be a novel treatment for
intimal hyperplasia of vein grafts.
Girdin depletion inhibits intimal hyperplasia in
vein grafts in vivo. Because the siRNAs targeting Girdin
(siRNA [B], si-rb1, si-rb2) had similar biological effects
in vitro (Figs 3 and 4, data not shown) and transfection with
si-rb2 tended to more strongly suppress Girdin expression
(Supplementary Fig 2, A, online only), we adopted thesequence of si-rb2 for the in vivo study. After initially con-
ﬁrming that stabilized siRNA (siSTABLE) retained inhibi-
tory effects equal to those of unmodiﬁed siRNA
(Supplementary Fig 2, B, online only), we used siSTABLE
for all animal experiments. Vein grafts were treated with
Girdin siRNA, as described in the Methods section. We
applied Girdin siRNA mixed with atelocollagen perivascu-
larly to vein grafts at operation (Supplementary Fig 3, A,
online only).
Western blot analysis conﬁrmed that Girdin siRNA
effectively suppressed Girdin expression in vein grafts
in vivo at least for 14 days postoperation (Fig 5, A); we
therefore evaluated its potential to inhibit intimal hyper-
plasia. At 4 weeks postoperation, the intimal thickness
and the intima-to-media ratio were 0.09 6 0.01 mm and
0.67 6 0.08, respectively, for vein grafts treated with
atelocollagen-mediated local application of Girdin siRNA
(n ¼ 5) and 0.22 6 0.05 mm and 1.76 6 0.24, respec-
tively, for grafts treated with atelocollagen containing irrel-
evant siRNA (n ¼ 5; Fig 5, B-D).
In addition, intimal thickness and the intima-to-media
ratio did not signiﬁcantly differ between vein grafts treated
with atelocollagen containing irrelevant siRNA and non-
treated grafts, indicating that controlled release of Girdin
siRNA using atelocollagen reduced intimal hyperplasia of
rabbit vein grafts signiﬁcantly (P < .05), whereas atelocol-
lagen alone had no effect. However, medial thickness did
not differ among the three groups at 4 weeks postoperation
(Supplementary Fig 3, B, online only).
Increased endothelial coverage reportedly correlates
with diminished intimal hyperplasia.22 To further investigate
the effects ofGirdin knockdown in vein grafts, we evaluated
re-endothelialization in vein grafts 7 days after bypass
grafting. Endothelial coverage in vein grafts was as-
sessed immunohistochemically using anti-CD31 antibody
(Supplementary Fig 4, A, online only). Quantiﬁcation
with image analysis showed no signiﬁcant difference in
endothelial coverage between Girdin siRNA-treated vein
grafts and control siRNA-treated grafts (Supplementary
Fig 4, B, online only). This suggests that the inhibitory effect
of Girdin knockdown on intimal hyperplasia was unrelated
to re-endothelialization.
Girdin is involved in cell proliferation, but not cell
survival, in vein grafts. Cell migration, cell proliferation,
and apoptosis of vascular SMCs are major steps in
intimal hyperplasia.23,24 To examine cell proliferation and
apoptosis in vein grafts, we performed Ki-67 immuno-
staining and TUNEL staining, respectively (Fig 6, A and
D). Vein grafts treated with Girdin siRNA showed signif-
icantly fewer Ki-67þ proliferating cells from media to
neointima at 7 days postoperation compared with vein
grafts treated with control siRNA (Fig 6, B). The media
and neointima were difﬁcult to distinguish at 7 days post-
operation. At 28 days postoperation, Ki-67þ cells signiﬁ-
cantly increased in the neointima but not in the media
(Fig 6, C). Conversely, cell survival in neither neointima
nor media was affected signiﬁcantly in vein grafts treated
with Girdin siRNA at any point (Fig 6, E and F). These
Fig 3. Girdin is required to rearrange actin cytoskeletons in venous smooth muscle cells (SMCs).A,Venous SMCs were
stained using anti-Girdin antibody and anti-b-actin antibody. Girdin localizes to actin stress ﬁbers. The scale bar¼ 20mm.
B,Venous SMCs transfectedwith control orGirdin small interferingRNA (siRNA; si-rb2)were stimulatedwith serum to
induce stress ﬁber formation, which was immunostained using anti-b-actin antibody. The scale bar ¼ 20 mm. C, Venous
SMCswere stimulatedwith platelet-derived growth factor (PDGF)-BB (20 ng/mL) for 10minutes and stainedwith anti-
b-actin antibody. The red dotted lines denote lamellipodia at the leading edge. The scale bar¼ 20 mm.D, In experiments
described in C, the increased number of cells with extended lamellipodia formation after PDGF stimulation was quan-
tiﬁed. The error bars show the standard error of the mean (n¼ 3 for each group). *P < .05. The inset shows a schematic
illustration of extended lamellipodia formation. Cells with lamellipodia at more than one-third (>120) of the cell
periphery were counted as cells with extended lamellipodia.
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proliferation but not cell survival.
DISCUSSION
Because we previously reported that Girdin depletion
reduces migration and proliferation of arterial SMCs,18
we hypothesized that Girdin knockdown would retard
intimal hyperplasia in vein grafts. Immunohistochemical
analyses conﬁrmed that Girdin localized to vascular
SMCs in the media and neointima of rabbit vein grafts.Girdin expression in the neointima peaked at w14 days
after implantation. These changes in Girdin expression in
vein grafts resembled those of vascular SMC proliferation
in vein grafts.25 In poor runoff models with abnormal
blood ﬂow conditions, as characterized by low ﬂow and
low shear stress variation mimicking clinical conditions of
vein grafts performed for ischemic extremities, intimal graft
thickening is more progressive than that in control models
with normal runoff.2,3 We showed that Girdin expression
in vein grafts with poor runoff was greater than that in
Fig 4. Depletion of Girdin inhibits venous smooth muscle cell (SMC) migration and proliferation in vitro. A, Venous
SMCs transfected with control or Girdin small interfering RNA (siRNA; si-rb2) were cultured in growth medium
containing 10% fetal bovine serum. Cells were allowed to migrate toward the wound for 12 hours. The scale bar ¼
300 mm.B,Ratio of themigration distance in each group at each time (n¼ 6 in each group).C,Number of cells that had
migrated into the wounded area (n ¼ 6 in each group). Three independent experiments were performed. The error bars
show the standard error of themean. *P< .05.D,Awater-soluble tetrazolium salt (WST)-1 assay was performed to assess
cell proliferation. Absorbance of each cell at day 0 was deﬁned as 1. The error bars show the standard error of the mean
(n ¼ 5). *P < .05. OD, Optical density.
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Girdin contributes to vascular SMC proliferation in vein
grafts and intimal hyperplasia after bypass grafting.
We isolated primary venous SMCs from enzyme-
dispersed neointima of rabbit vein grafts 4 weeks postopera-
tion. These primary cells, apparently originating from
various cell types, exhibited increased migration and prolif-
eration shortly after being isolated. In contrast, cells isolated
from vein grafts 8 weeks postoperation in the same way did
not migrate readily and rarely underwent mitosis in the ﬁrst
few days (data not shown). In this study, we isolated primary
venous SMCs from the neointima of vein grafts by the
enzyme dispersion method, although isolation of venous
SMCs by the explant method has recently been reported.26
We suppose that cells prepared in this way reﬂect the form of
vascular SMCs in the vein graft more exactly than those iso-
lated from explants of vena cava or saphenous veins, because
cell types from neointimal SMCs are different from those ofmedial SMCs,27 and the enzyme dispersion method is
known to retain characteristic features of in vivo cells.28
Our data showed that Girdin localized to venous SMCs,
especially in the neointima of vein grafts 14 days after
implantation, rather than those in the media.
Plausibly, Girdin might be expressed in dedifferentiated
vascular SMCs and affect phenotypic modulation in
vascular SMCs because vein graft neointima have abundant
dedifferentiated vascular SMCs.21 To examine this hypoth-
esis, we stimulated venous SMCs with PDGF-BB (a known
inducer of phenotypic switch in vascular SMCs) containing
10% fetal bovine serum, which markedly enhanced Girdin
expression (Supplementary Fig 5, A, online only) and led
to morphologic change (Supplementary Fig 5, B, online
only). Although our data suggest that Girdin is upregulated
in dedifferentiated vascular SMCs, further studies are
needed to understand the role of Girdin in vascular SMC
phenotypic modulation.
Fig 5. Depletion of Girdin inhibits intimal hyperplasia in vein grafts in vivo. A, Western blot analyses show efﬁcacy of
the treatment with atelocollagen containing Girdin small interfering RNA (siRNA) in whole-vein grafts at 7 and
14 days postoperation. The bar graph shows relative protein levels of Girdin determined by densitometry. The error
bars show the standard error of the mean (n ¼ 3). *P < .05. B, Representative elastica Van Gieson-stained sections
from animals at 4 weeks postoperation, with or without Girdin siRNA treatment. Representative photographs at
(upper panel) low (scale bar ¼ 1.0 mm) and (lower panel) high (scale bar ¼ 100 mm) magniﬁcations are presented.
Signiﬁcant reduction was seen in (C) intimal thickness and the (D) intima/media ratio in vein grafts treated with
Girdin siRNA at 4 weeks postoperation. The error bars indicate the standard error of the mean (n ¼ 5 for each group).
*P < .05.
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delivery to the vasculature remains somewhat elusive.
Such a vector should efﬁciently transduce target vascular
cells with minimal transduction of nontarget cells, have
low toxicity and immunogenicity, and be sufﬁciently stable
to allow longevity of transgene expression, leading to an
adequate clinical response.29 Although the most commonly
used vector is an adenovirus, viral vectors pose three main
limitations in human vascular gene therapy: (1) common
pre-existing immunity to the adenovirus, (2) profound
immune response generated to adenoviral-transduced cells,
and (3) direct tissue toxicity.30 Many trials, including
genetic interventions to prevent vein graft failure, take
advantage of the fact that veins to be grafted can be manip-
ulated ex vivo. Antisense or decoy oligodeoxynucleotides
have been transfected into vein graft walls by usingliposomes or high pressure.31-35 Newer methods, such as
ultrasound or gene guns, deliver desired genes by nonviral
vectors; for example, plasmids through cellular walls.36
This strategy, however, allows a drug to be administered
only once, and most of the applied drug remains at the
application site relatively brieﬂy. Because neointimal
SMCs have three potential sourcesdvein grafts, arterial
walls, and circulating blooddsingle treatments for vein
grafts are probably insufﬁcient.7
Here, we used atelocollagen to deliver siRNA. Atelocol-
lagen is a liquid at 4C and becomes solid at 37C. It has
been used as a delivery system for expression plasmids, anti-
sense oligodeoxynucleotides, and siRNAs because it stabi-
lizes and slowly releases nucleic acid reagents.37-39 Thus,
siRNA is retained at the application site, allowing long-
lasting target gene suppression in vascular SMCs without
Fig 6. Cell proliferation and survival in vein grafts postoperation.A,Ki-67-immunostained sections of vein grafts treated
with Girdin small interfering RNA (siRNA) or control siRNA. The scale bar¼ 100 mm. B, Percentage of Ki-67þ cells in
area inside of vein graft internal elastic lamina 7 days postoperation. C, Percentage of Ki-67þ cells in the media or intima
of vein grafts 28 days postoperation. The error bars indicate the standard error of the mean (day 7, n¼ 3; day 28, n¼ 5).
*P < .05.N.S.,Not signiﬁcant.D, Vein grafts underwent terminal deoxynucleotide transferase-mediated deoxy uridine
triphosphate nick-end labeling (TUNEL) staining at 7 or 28 days postoperation. The scale bar¼ 100 mm. E, Percentage
of TUNELþ cells in the area inside of the vein graft internal elastic lamina 7 days postoperation. F, Percentage of
TUNELþ cells in the media and intima of vein grafts 28 days postoperation. The error bars indicate the standard error of
the mean (day 7, n ¼ 3; day 28, n ¼ 5). N.S., Not signiﬁcant.
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Volume 60, Number 2 Miyachi et al 487regard to cell origin. Also, siRNA was retained at the appli-
cation site 7 days postoperation, as found in a study using
ﬂuorescence-labelled siRNA.20
We conﬁrmed that Girdin expression was suppressed for
at least 14 days using atelocollagen-mediated siRNA target-
ingGirdin.We also showed that Girdin expression peaked at
w14 days after bypass grafting and that treatment with
atelocollagen-mediated siRNA targeting Girdin signiﬁ-
cantly inhibited intimal hyperplasia in vein grafts 28 days
postoperation. Conversely, Girdin depletion did not affect
medial thickness 28 days postoperation (Supplementary
Fig 3, B, online only), although neointimal SMCs may be
derived from the media without enhanced proliferation of
medial SMCs (Fig 6, C). The mechanism by which GirdinsiRNA inhibits intimal hyperplasia remains unclear. Notably,
Girdin depletion did not affect re-endothelialization in vein
grafts, which is an important response consideration in
bypass grafting.22,40 Our study indicates that suppressing
Girdin in vein grafts could be a useful strategy for preventing
vascular stenosis.CONCLUSIONS
Girdin is pivotal to migration and proliferation of
venous SMCs isolated from the neointima of rabbit vein
grafts. We conﬁrmed that the combination of atelocollagen
and siRNA to allow controlled siRNA release could be
a novel therapeutic strategy for vein graft failure and that
JOURNAL OF VASCULAR SURGERY
488 Miyachi et al August 2014Girdin is a potential molecular target for prevention of
intimal hyperplasia in vein grafts in vivo.
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Western blot analysis. After sodium dodecyl sulfate-
electrophoresis, proteins were transferred to polyvinylidene
ﬂuoride membranes (Millipore Corp, Bedford, Mass).
Membranes were blocked in 5% skim milk in Tris-buffered
saline with Tween buffer (20-mM Tris-HCl [pH 7.6],
137-mM NaCl, 0.1% Tween 20), with gentle agitation,
and incubated with the primary antibody. The membranes
were washed with Tris-buffered saline with Tween buffer
and incubated with secondary antibody conjugated to
horseradish peroxidase. After the membranes were washed,
the reaction was visualized by the ECL Detection Kit (GE
Healthcare, Buckinghamshire, United Kingdom), accord-
ing to manufacturer’s instructions.
Immunoﬂuorescence staining. Venous smooth
muscle cells (SMCs) were plated on culture slides. Cells
were ﬁxed with methanol and 4% paraformaldehyde,
blocked with 3% bovine serum albumin in phosphate-
buffered saline, and stained with anti-b-actin antibody
and the rabbit polyclonal anti-Girdin antibody overnight
at 4C. They were then incubated with Alexa Fluor 488-
conjugated goat anti-mouse immunoglobulin G (IgG)
antibody and Alexa Fluor 594-conjugated goat anti-rabbit
IgG antibody (Invitrogen, Carlsbad, Calif) for 1 hour.
Fluorescence was examined using confocal laser-scanning
microscopy (Fluoview FV500; Olympus, Tokyo, Japan).
In rabbit vein grafts, transverse sections (4 mm) were
blocked with Protein Block Serum-Free Ready-to-Use(Dako, Glostrup, Denmark) and incubated with a mouse
monoclonal anti-a-smooth muscle actin antibody and
sheep polyclonal anti-Girdin antibody overnight at 4C.
Thereafter, the sections were incubated with donkey anti-
mouse IgG antibody conjugated with Alexa Fluor 488
and anti-sheep IgG antibody conjugated with Alexa Fluor
594. 40,6-Diamidino-2-phenylindole was used as counter-
stain.
Cell migration assay. Venous SMCs were seeded on
35-mm glass-bottom dishes and transfected with control
or Girdin small interfering RNA. Conﬂuent cells were
scratched with a 200-mL disposable plastic pipette tip and
allowed to migrate toward the wound. Wounded cells
were incubated with 10% fetal bovine serum in Dulbecco’s
Modiﬁed Eagle’s Medium at 37C, and digital images were
taken with an IX70 microscope (Olympus). Wound closure
rates were calculated as percentages of migratory distances
of control cells (100%).
Mitogenic assay. Venous SMCs (2.0  104 cells/well)
transfected with control or Girdin small interfering RNA
were plated in 96-well plates 48 hours after transfection
and allowed to proliferate for 2 or 4 days with Dulbecco’s
Modiﬁed Eagle’s Medium containing 10% fetal bovine
serum. Cell Proliferation Reagent WST-1 assay (Roche
Applied Science, Penzberg, Germany) reagent (10 mL)
was added to 100 mL of cell suspension and incubated
for 4 hours. The absorbance of each well was measured
at 450 nm using a microplate reader.
Supplementary Fig 1 (online only). Girdin localizes to venous smooth muscle cells (SMCs) in the vessel walls of
intact veins. Upper panels, Rabbit intact veins were assessed with immunohistochemical analysis using anti-Girdin and
anti-a-smooth muscle actin (SMA) antibodies. Note that these veins were dilated with infusion pressure during ﬁxation,
and vascular walls look thinner than under normal conditions. Lower panels, The boxed areas are magniﬁed. The scale
bar ¼ 100 mm.
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Supplementary Fig 2 (online only). Effects of small interfering RNA (siRNA) on Girdin expression in cultured cells.
A, Venous smooth muscle cells (SMCs) were transfected with three types of Girdin siRNAs or control siRNA, or were
not treated (normal). A representative Western blot for Girdin is shown. Relative densitometric intensities of Western
blot bands for Girdin are presented as means 6 standard error of the means in the graph (n ¼ 3). B, Stabilized siRNA
(siSTABLE) retained inhibitory effects equal to those of unmodiﬁed siRNA (n ¼ 3).
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Supplementary Fig 3 (online only). Local application of atelocollagen-mediated small interfering RNA (siRNA).
A, siRNA mixed with atelocollagen was used to coat external surfaces of the vein graft (VG). CCA, Common carotid
artery; ECA, external carotid artery; ICA, internal carotid artery. B, There were no signiﬁcant differences in medial
thickness among vein grafts nontreated and treated with Girdin siRNA or control siRNA at 4 weeks postoperation. The
error bars indicate the standard error of the mean (n ¼ 5 for each group).
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Supplementary Fig 4 (online only). Immunohistochemical analysis of vein grafts using anti-CD31 antibody.
A, Representative immunostaining with anti-CD31 antibody. The scale bar ¼ 100 mm. B, Percentage of luminal
coverage by endothelial cells. The error bars indicate the standard error of the mean (n ¼ 3 per each group). N.S., Not
signiﬁcant.
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Supplementary Fig 5 (online only). Girdin expression level in phenotypic modulation in venous smooth muscle cells
(SMCs). A,Western blot analyses show Girdin protein levels in venous SMCs treated with transforming growth factor-
b (TGF-b; 2.5 mg/L), platelet-derived growth factor (PDGF)-BB (25 mg/L), 10% fetal bovine serum (FBS), or both
FBS and PDGF-BB for 48 hours. Relative densitometric intensities of Western blot bands of Girdin are presented as
means 6 standard error of the mean in the graph. Girdin protein level in serum-starved venous SMCs [serum(e)] was
deﬁned as 1 (n ¼ 3). B,Morphologic changes in venous SMCs with indicated stimulation for 48 hours. The scale bar ¼
60 mm.
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